References
- OECD/WHO. “Mortality from Cardiovascular Disease”, in Health at a Glance: Asia/Pacific 2012: OECD Publishing. [online] 2012. [cited 2014 Feb 28]; Available from: http://dx.doi.org/10.1787/9789264183902-8-en
- Kromhaut D, Bosschieter E, de Lezenne Coutander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985; 312:1205-9.10.1056/NEJM1985050931219013990713
- Singh R, Niaz M, Sharma J, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebocontrolled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian Experiment of Infarct Survival. Cardiovasc Drug Ther. 1997; 11:485-91.10.1023/A:1007757724505
- Albert C, Hennekens C, O’Donnell C, Ajani U, Carey V, Willet W, et al. Fish consumption and risk of sudden cardiac death. JAMA. 1998; 279:23-8.942403910.1001/jama.279.1.23
- GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial [errata in Lancet 2001;357:642 and Lancet 2007;369:106]. Lancet. 1999; 354:447-55.
- Burr M, Gilbert J, Holliday R, Elwood P, Fehily A, Rogers S, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989; 2: 757-61.2571009
- Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebocontrolled trial to test the effect of highly purified omega-3 fatty acids on top of modern guidelineadjusted therapy after myocardial infarction. Circulation. 2010; 122:2152-9.10.1161/CIRCULATIONAHA.110.948562
- The ORIGIN Trial Investigators. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012; 367:309-18.22686415
- Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010; 341: c6273.2111558910.1136/bmj.c6273
- Kromhout D, Giltay E, Geleijnse J, for the Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010; 363:2015-26.2092934110.1056/NEJMoa1003603
- Hooper L, Harrison R, Summerbell C, Moore H, Worthington H, Ness A, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease (review). Cochrane Database Syst Rev. 2009; CD003177.
- Rizos E, Ntzani E, Bika E, Kostapanos M, Elisaf M. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012; 308:1024-33.10.1001/2012.jama.1137422968891
- Marik P, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009; 32:365-72.1960989110.1002/clc.20604
- Bucher H, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002; 112:298-304.10.1016/S0002-9343(01)01114-711893369
- Leon H, Shibata M, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki R. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2009; 338: a2931.
- Kwak S, Myung S, Lee Y, Seo H, for the Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease. Arch Intern Med. 2012; 172:686-94.10.1001/archinternmed.2012.262
- Mozaffarian D, Rimm E. Fish intake, contaminants, and human health evaluating the risks and the benefits. JAMA. 2006; 296:1885-99.1704721910.1001/jama.296.15.1885
- Marchioli R, Schweigerb C, Tavazzi L, Valagussad F. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Lipids. 2001; 36(Suppl.):S119-26.11837985
- GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet. 2008; 372:1223-30.
- Report of Consumer Price Index of Thailand Year 2003-2013 (BASE YEAR 2011): Bureau of Trade and Economic Indices, Ministry of Commerce. [online] 2013. [cited 2013 Nov 27]; Available from: http://www.indexpr.moc.go.th/price_present/TableIndexG_region.asp?table_name=cpig_index_country&province_code=&type_code=g&check_f=i&year_base=2554&nyear=2546
- Anukoolsawat P, Sritara P, Teerawattananon Y. Costs of lifetime treatment of acute coronary syndrome at Ramathibodi Hospital. Thai Heart J. 2006; 19:132-43.
- Khiaocharoen O, Pannarunothai S, Riewpaiboon W, Ingsrisawang L, Teerawattananon Y. Economic evaluation of rehabilitation services for inpatients with stroke in Thailand: a prospective cohort study. Value Health Region Issues. 2012; 1:29-35.10.1016/j.vhri.2012.03.021
- Tsevat J, Goldman L, Soukup J, Lamas G, Connors K, Chapin C, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993; 13:161-5.848340110.1177/0272989X9301300210
- Wannasiri Y, Kapol N. The health utility of stroke patients at Ratchaburi Hospital (in Thai). Region 4-5 Med J. 2010; 29:95-103.
- Liew D, De Abreu Lourenco R, Adena M, Chim L, Aylward P. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Clin Ther. 2013; 35:1110-7.2389136110.1016/j.clinthera.2013.06.015
- Calvert M, Freemantle N, Cleland J. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005; 7:243-51.1570147410.1016/j.ejheart.2005.01.012
- Kraai I, Vermeulen K, Luttik M, Hoekstra T, Jaarsma T, Hillege H. Preferences of heart failure patients in daily clinical practice: quality of life or longevity. Eur J Heart Fail. 2013; 15:1113-21.2365013010.1093/eurjhf/hft071
- Limwattananon S. Sensitivity analysis for uncertainty variables used in the model. In: Chaikletkaow U, Teerawattananon Y, editors. Guideline of Health Technology Assessment for Thailand. 2. Bangkok: Chulalongkorn University Book Center; 2013. p. 105-8.
- Gerlier L, Vellopoulou K, Lamotte M, Lacey L, Einroos A, Carr E. A health economic evaluation of omega-3 acid ethyl esters 90 in the secondary prevention post-MI in Ireland and Estonia. Abstract presented in ISPOR 15th Annual European Congress. 2012; 15:A373.
- Quilici S, Martin M, McGuire A, Zoellner Y. A costeffective analysis of n-3 PUFA (Omacor) treatment in post-MI patients. J Clin Prac. 2006; 60:922-32.10.1111/j.1742-1241.2006.01009.x
- Lamotte M, Annemans L, Kawalec P, Zoellner Y. A multi-country health economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Pharmacoeconomics. 2006; 24:783-95.10.2165/00019053-200624080-0000516898848